Asia Pacific Gaucher Disease Drugs Market Size & Outlook
Asia Pacific gaucher disease drugs market highlights
- The Asia Pacific gaucher disease drugs market generated a revenue of USD 307.8 million in 2023.
- The market is expected to grow at a CAGR of 3.4% from 2024 to 2030.
- In terms of segment, type 1 was the largest revenue generating type in 2023.
- Type 1 is the most lucrative type segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2023 | USD 307.8 million |
| Market revenue in 2030 | USD 390.3 million |
| Growth rate | 3.4% (CAGR from 2023 to 2030) |
| Largest segment | Type 1 |
| Fastest growing segment | Type 1 |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Type 1 |
| Key market players worldwide | Sanofi SA, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Johnson & Johnson, ERAD Therapeutics |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 18.1% of the global gaucher disease drugs market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 390.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gaucher Disease Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| ERAD Therapeutics | View profile | - | Potomac, Maryland, United States, North America | https://www.eradtx.com/ |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Asia Pacific gaucher disease drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gaucher disease drugs market will help companies and investors design strategic landscapes.
Type 1 was the largest segment with a revenue share of 100% in 2024. Horizon Databook has segmented the Asia Pacific gaucher disease drugs market based on type 1 covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Asia Pacific gaucher disease drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific gaucher disease drugs market databook
-
Our clientele includes a mix of gaucher disease drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific gaucher disease drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific gaucher disease drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
